– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end

–PALI-2108正在开发中，用于治疗中重度溃疡性结肠炎（UC），在年底前进入1期临床研究

Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA..

加利福尼亚州卡尔斯巴德，2024年4月10日（环球通讯社）--Palisade Bio Inc.（纳斯达克：PALI）（“Palisade”，“Palisade Bio”或“公司”）是一家生物制药公司，专注于为患有自身免疫性，炎症性和纤维化疾病的患者开发和推进新型治疗方法，今天宣布将于2024年4月9日至10日在马萨诸塞州剑桥举行的IBD Innovate:Crohn's＆Colitis™产品开发会议上发布。。

As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development.

作为会议的一部分，该公司的研究合作伙伴Giiant Pharma，Inc.的首席执行官Christophe Mellon和Palisade Bio的首席医疗官Mitch Jones博士进行了题为“推进PALI-2108：从发现到战略定位”的口头演讲，讨论了PALI-2108的发展，其在竞争格局中的差异化和定位，以及通向后期发展的临床途径。

The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com..

该演示文稿可在Palisade Bio网站（www.palisadebio.com）科学部分的出版物页面上访问。。

“We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year,' commented Dr. Jones..

“我们很高兴与Giiant一起参加IBD总理会议，并提供有关PALI-2108的更多信息。琼斯博士评论道：“我们继续从PALI-2108中产生越来越多的用于治疗UC的数据，并有望在今年晚些时候启动我们的第一阶段临床研究。”。。

As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.

如前所述，PALI-2108的开发得到了美国克罗恩病和结肠炎基金会通过其IBD风险投资计划与Giiant达成的50万美元研究计划资助协议的支持。

PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

PALI-2108是一种口服，局部作用的结肠特异性磷酸二酯酶-4（PDE4）抑制剂前药，正在为受UC影响的患者开发。

About IBD Innovate

关于IBD创新

The Crohn's & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet needs of patients with IBD. In pursuit of this objective, the foundation launched IBD Ventures to directly fund product discovery and development.

克罗恩病和结肠炎基金会寻求加速发现和开发新产品，以解决IBD患者未满足的需求。为了实现这一目标，基金会启动了IBD Ventures，直接资助产品发现和开发。

IBD Innovate is the premier IBD product development conference for therapeutics, diagnostics, devices, and digital health.

IBD Innovate是针对治疗、诊断、设备和数字健康的首屈一指的IBD产品开发会议。

About Palisade Bio

关于Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com..

Palisade Bio是一家生物制药公司，专注于为患有自身免疫性，炎症性和纤维化疾病的患者开发和推进新型疗法。该公司相信，通过对其新型疗法采用有针对性的方法，它将改变治疗格局。欲了解更多信息，请访问www.palisadebio.com。。

Forward Looking Statements

前瞻性声明

This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S.

本信函包含1995年《私人证券诉讼改革法案》安全港条款中的“前瞻性”声明。前瞻性陈述包括有关公司意图、信念、预测、前景、分析或当前预期的陈述，其中包括：我们的现金周转范围；我们成功开发许可技术的能力；对我们候选产品市场的规模和增长潜力以及我们服务这些市场的能力（包括产生的任何潜在收入）进行估计；美国和外国未来的监管、司法和立法变化或发展以及这些变化的影响；我们维持证券在纳斯达克上市的能力；我们在美国建立商业基础设施的能力。

and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply.

和其他市场；我们在竞争激烈的行业中有效竞争的能力；我们能够识别和鉴定制造商以提供API和制造药品；我们签订商业供应协议的能力；现有或可能获得的竞争技术的成功；我们吸引和留住关键科学或管理人员的能力；我们对费用、未来收入、资本要求和额外融资需求的估计准确性；我们获得运营资金的能力；我们吸引合作者和战略合作伙伴的能力；以及新型冠状病毒大流行或任何全球性事件对我们的业务、运营和供应的影响。

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s cu.

本通讯中包含的任何不属于历史事实陈述的陈述均可被视为前瞻性陈述。这些前瞻性声明基于公司的cu。

Investor Relations Contact

投资者关系联系人

JTC Team, LLC

JTC团队有限责任公司

Jenene Thomas

珍妮·托马斯

833-475-8247

833-475-8247

PALI@jtcir.com

PALI@jtcir.com